Antonio D'Avolio

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. ncbi Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy Electronic address
    Antiviral Res 100:114-9. 2013
  2. doi Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
    Antonio D'Avolio
    Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Pharmacogenet Genomics 23:293-300. 2013
  3. doi Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 34:722-8. 2012
  4. doi Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Antimicrob Chemother 68:907-10. 2013
  5. doi A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 78:217-23. 2013
  6. doi Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetic, Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 66:376-80. 2012
  7. doi HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 59:109-16. 2012
  8. doi Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
    Antonio DʼAvolio
    Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Italy
    Ther Drug Monit 34:165-70. 2012
  9. pmc Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
    Chiara Tommasi
    National Institute for Infectious Diseases L, Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Malar J 10:141. 2011
  10. doi HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Pharm Biomed Anal 52:774-80. 2010

Collaborators

Detail Information

Publications50

  1. ncbi Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy Electronic address
    Antiviral Res 100:114-9. 2013
    ..Considering the characterization of pre-therapy anemia predictors, rs6051702 SNP in association to rs1127354 is more informative in order to avoid this relevant adverse event. ..
  2. doi Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
    Antonio D'Avolio
    Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Pharmacogenet Genomics 23:293-300. 2013
    ..The aim of this study was to assess the potential impact of the pharmacogenetic variability of CYP2B6 and ABCB1 genes on the pharmacokinetics of mitotane...
  3. doi Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 34:722-8. 2012
    ..The aim of our study was to carry out an integrated analysis of the effects of polymorphisms and ribavirin (RBV) plasma exposure on outcome...
  4. doi Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Antimicrob Chemother 68:907-10. 2013
    ..Therefore, our aim was to evaluate intracellular ritonavir penetration when used with different boosted PIs in the clinical setting...
  5. doi A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 78:217-23. 2013
    ..22 (IQR 1.10-1.33) and 1.52 (IQR 1.21-1.67), respectively. The use of this simple assay method could be an important tool for management of HCV-1 DAAs treated patients...
  6. doi Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetic, Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 66:376-80. 2012
    ..0%. We tested this method by monitoring blood ribavirin concentrations in 13 HCV+ patients, receiving alpha interferon-plus ribavirin combination therapy...
  7. doi HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 59:109-16. 2012
    ....
  8. doi Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
    Antonio DʼAvolio
    Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Italy
    Ther Drug Monit 34:165-70. 2012
    ..However, no definitive data are yet available on the role of plasma RBV concentrations on hemoglobin (Hb) decrement. Moreover, no data have been published on the possible interplay between these 2 factors...
  9. pmc Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
    Chiara Tommasi
    National Institute for Infectious Diseases L, Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Malar J 10:141. 2011
    ..The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450...
  10. doi HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Pharm Biomed Anal 52:774-80. 2010
    ....
  11. doi A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 32:86-92. 2010
    ..The new high-performance liquid chromatography-ultraviolet method reported here could be used routinely to monitor plasma concentrations of maraviroc in healthy volunteers and HIV-infected patients...
  12. doi A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation
    Antonio D'Avolio
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, Turin, Italy
    J Pharm Biomed Anal 54:779-88. 2011
    ..This analytical method is routinely used in our clinical research center for the assessment of intracellular levels of all PIs, raltegravir and NNRTIs commercially available at present...
  13. ncbi An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 30:662-9. 2008
    ....
  14. ncbi A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164 10149 Turin ITALY
    J Chromatogr Sci 46:524-8. 2008
    ..The method was applied for the determination of antiretroviral plasma concentration of HIV-positive patients treated with FTC and/or TNF, in combination with various other antiretrovirals...
  15. ncbi Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide
    Daniel Gonzalez de Requena
    Department of Infectious Diseases, University of Turin, Turin, Italy
    AIDS 20:1977-9. 2006
    ..This unexpected drug-drug interaction warrants further investigation...
  16. doi New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
    Silvia De Francia
    Department of Biological and Clinical Sciences, University of Torino, S Luigi Gonzaga Hospital, 10043 Orbassano TO, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1721-6. 2009
    ....
  17. doi Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients
    Stefano Bonora
    Department of Infectious Diseases of the University of Torino, Amedeo di Savoia Hospital, Torino, Italy
    Antivir Ther 16:499-504. 2011
    ..In order to improve ATV exposure, plasma and intracellular (IC) PK of ATV in patients administered with ATV 400 mg once daily and TDF/emtricitabine (FTC) and switched to ATV 200 mg twice daily were studied...
  18. pmc Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens
    Daniel Gonzalez de Requena
    Department of Infectious Diseases, University of Turin, Turin, Italy
    Antimicrob Agents Chemother 52:1066-71. 2008
    ..A possible TPV gIQ cutoff value of 14,500 for reaching a VR at week 48 was suggested. Further studies are needed in order to evaluate the calculation of TPV gIQ as a new tool for the optimization of TPV-based salvage therapy...
  19. doi Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
    Lucio Boglione
    Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
    Liver Int 33:580-5. 2013
    ..Thus, in this type of patients the main goals of antiviral therapy is the suppression of HBV-DNA and ALT normalization...
  20. doi Ceftriaxone bone penetration in patients with septic non-union of the tibia
    Silvia Garazzino
    Department of Infectious Diseases, University of Turin, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Turin, Italy
    Int J Infect Dis 15:e415-21. 2011
    ..Data on ceftriaxone (CFX) bone penetration are lacking. We measured CFX concentrations in infected bone to verify their relationship with pharmacodynamic microbiological markers...
  21. doi Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV
    Lorena Baietto
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 31:104-9. 2009
    ..156 microg/mL for MOXI, and 0.622 microg/mL for RFP. This method allows the simultaneous measurement of LEVO, LZD, MOXI, and RFP in human plasma and may be used for both routine clinical applications and pharmacokinetic studies...
  22. doi Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients
    Daniel Gonzalez de Requena
    Department of Infectious Diseases, University of Turin, Turin, Italy
    J Antimicrob Chemother 62:384-7. 2008
    ..The relationship between enfuvirtide plasma exposure and VR has not yet been investigated in the clinical setting. Our aim was to investigate the role of enfuvirtide plasma exposure as a determinant of early VR in the clinical setting...
  23. pmc Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations
    Marco Simiele
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    Antimicrob Agents Chemother 55:2976-8. 2011
    ..0; maximum, 354.6), with a standard deviation of 8.8%. Previous reports have often used a fixed value of 400 fl for the MCV, which may result in artificially low estimates of the intracellular concentrations of antivirals...
  24. pmc Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma
    Lorena Baietto
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    Antimicrob Agents Chemother 54:3408-13. 2010
    ..031 microg/ml for itraconazole and posaconazole and 0.039 microg/ml for voriconazole. The calibration range tested was from 0.031 to 8 microg/ml for itraconazole and posaconazole and from 0.039 to 10 microg/ml for voriconazole...
  25. doi Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens
    Daniel Gonzalez de Requena
    Department of Infectious Diseases, University of Torino, Torino, Italy
    J Antimicrob Chemother 66:192-200. 2011
    ..The aim of our study was to compare seven different free-access resistance algorithms and their derived gIQs as predictors of 48 week virological response to darunavir-based salvage therapy in the clinical setting...
  26. pmc Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices
    Andrea Calcagno
    Department of Infectious Diseases, University of Torino, Torino, Italy
    Br J Clin Pharmacol 74:134-40. 2012
    ..Pharmacokinetic/pharmacogenetic (PK/PG) studies are difficult to perform in remote areas where refrigeration is not available, although dried plasma and dried blood methods have been validated...
  27. ncbi Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment
    Andrea Calcagno
    From the Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
    Scand J Infect Dis 45:882-4. 2013
    ..5 μg/ml*h vs. 108.8 μg/ml*h). Although rifampin-mediated complete enzyme induction may take longer than 2 weeks, the clinical advantage of an increased caspofungin dose deserves clinical investigation...
  28. doi Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots
    Lorena Baietto
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149, Turin, Italy Electronic address
    J Chromatogr B Analyt Technol Biomed Life Sci 936:42-7. 2013
    ..Linear regression analysis confirmed that the two methods of extraction have good correlation. Thus they are suited for TDM of linezolid and for pharmacokinetic studies. ..
  29. doi Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS
    Lorena Baietto
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Antimicrob Chemother 67:2645-9. 2012
    ..We aimed to develop and validate a new method to analyse itraconazole, posaconazole and voriconazole in plasma spotted on dry sample spot devices (DSSDs) and to quantify them by an HPLC system...
  30. doi Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics
    Andrea Calcagno
    Department of Infectious Diseases, University of Torino, Torino, Italy
    AIDS 26:1529-33. 2012
    ....
  31. ncbi A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
    Antonio D'Avolio
    Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 848:374-8. 2007
    ..Concentration range when optimized (0.703-180 microg/ml) proved to be adequate to measure tipranavir concentration in HIV-1-positive patients, therefore this method could be suitable for therapeutic drug monitoring of this drug...
  32. doi Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
    Lorena Baietto
    Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, Turin 10149, Italy
    Anal Bioanal Chem 396:791-8. 2010
    ..A rapid, specific, sensitive, accurate, and reproducible HPLC method was developed and validated to measure daptomycin, amikacin, gentamicin, and rifampicin in human plasma. This method is suitable for clinical pharmacokinetic studies...
  33. pmc Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir
    Marco Siccardi
    Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
    Clin Infect Dis 47:1222-5. 2008
    ..008) and 5.13 (P = .02). Prospective studies determining potential clinical usefulness are now warranted...
  34. ncbi Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera, 164 10149 Turin, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 835:127-30. 2006
    ..The assay warrants further evaluation as a tool for ribavirin therapeutic drug monitoring in HCV-positive patients...
  35. doi Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
    Marco Siccardi
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Torino, Italy
    Pharmacogenet Genomics 20:759-65. 2010
    ..The 521 T>C polymorphism has been correlated earlier with higher plasma concentrations of several drugs and the aim of this study was to determine whether this polymorphism influences trough concentrations of maraviroc...
  36. doi A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera, Turin, Italy
    Ther Drug Monit 30:90-4. 2008
    ..58%). The method was linear from 0.59 to 150 microg/mL and reproducible. In conclusion, this method allows the measurement of ertapenem in human plasma and may be used for both clinical routine applications and pharmacokinetic studies...
  37. ncbi HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 859:234-40. 2007
    ..In our hand, it was used to measure DRV and ritonavir plasma concentration in HIV-positive patients, and it is now successfully applied for routine therapeutic drug monitoring and pharmacokinetics studies...
  38. ncbi Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms
    Lucio Boglione
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy Electronic address
    Antiviral Res 106:105-10. 2014
    ..In our paper we propose the use of both rs8099917 and rs12979860 IL28-B polymorphisms, in order to identify potentially categories of SVR, null-responder and relapse and consequently to choose the dual therapy or novel approach...
  39. ncbi Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots
    Lorena Baietto
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Turin, Italy
    J Pharm Biomed Anal 88:66-70. 2014
    ..919). DPS represents a safe and cheap strategy to store and ship plasma samples. Thus, it is suited for pharmacokinetic studies and therapeutic drug monitoring of daptomycin in hospitals without a therapeutic drug monitoring laboratory. ..
  40. ncbi An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients
    Antonio D'Avolio
    Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 28:110-5. 2006
    ..Therefore, this method can be used as a reliable tool for pharmacokinetic studies of enfuvirtide...
  41. ncbi Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients
    Danilo Agnesod
    Laboratory of Clinical Pharmacology and Pharmacogenetic Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 90:119-26. 2014
    ..This method showed to be reliable, precise, accurate and suitable for evaluation of intracellular RBV concentrations...
  42. doi Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia
    Silvia Garazzino
    Department of Infectious Diseases, University of Turin, Turin, Italy
    Clin Pharmacokinet 47:793-805. 2008
    ....
  43. doi A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma
    Marco Simiele
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Pharm Biomed Anal 94:65-70. 2014
    ..The HPLC-MS method reported here could be used routinely to monitor plasma concentrations of maraviroc in HIV-infected patients. ..
  44. doi High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis
    Andrea Calcagno
    Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
    J Antimicrob Chemother 69:241-5. 2014
    ..To analyse the determinants of raltegravir CSF penetration, including the pharmacogenetics of drug transporters located at the blood-brain barrier or blood-CSF barrier...
  45. ncbi Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines
    Francesco Giuseppe De Rosa
    Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital City of Science and Health Molinette, Hospital Pharmacy, Turin, Italy
    Infez Med 22:107-11. 2014
    ..Our brief analysis of randomized trials, whereby recommendations are supported, aims to discuss the possible reasons for the different consideration of fluconazole by the two above mentioned guidelines. ..
  46. ncbi The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon
    Lucio Boglione
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C so Svizzera 164, Turin, Italy Electronic address
    J Infect 69:81-7. 2014
    ..We describe the epidemiological and clinical characteristics in a cohort of patients immigrants from Africa in our country with HBV E genotype chronic hepatitis infection (CHB)...
  47. doi Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon
    Lucio Boglione
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Antiviral Res 102:35-43. 2014
    ..057; CI=0.014-0.238; p<0.001). IL28-B polymorphisms are related to different response in the treatment of CHB HBeAg-negative with PEG-IFN, and the E genotype is a novel negative predictive factor. ..
  48. doi Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma
    Antonio D'Avolio
    Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital and Pharmacy Department, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 35:853-8. 2013
    ..This concentration range proved to be adequate to measure tigecycline concentrations in patients treated with the drug, therefore this method would be suitable for therapeutic drug monitoring. ..
  49. ncbi Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort
    Andrea Marengo
    Gastro Hepatology Unit, San Giovanni Battista Hospital, University of Turin, Italy
    Antivir Ther 18:87-94. 2013
    ....
  50. doi Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia
    Lucio Boglione
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    J Clin Virol 56:167-9. 2013
    ....